<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00343369</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000455738</org_study_id>
    <secondary_id>GER-COALL-07-03</secondary_id>
    <secondary_id>EU-205104</secondary_id>
    <nct_id>NCT00343369</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Multicentric Study for the Treatment of Children With Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer
      cells, either by killing the cells or by stopping them from dividing. Giving more than one
      drug (combination chemotherapy) may kill more cancer cells. It is not yet known which
      combination chemotherapy regimen is more effective in treating acute lymphoblastic leukemia.

      PURPOSE: This randomized phase III trial is studying different combination chemotherapy
      regimens to compare how well they work in treating young patients with acute lymphoblastic
      leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the dose of daunorubicin hydrochloride that is equivalent to 30 mg/m² of
           doxorubicin hydrochloride in pediatric patients with acute lymphoblastic leukemia (ALL).

        -  Determine whether it is possible to reduce therapy in pediatric patients with low-risk
           ALL and a PVA (prednisolone-vincristine-asparaginase) score of 3+4 without loss of
           efficacy.

        -  Investigate the role of single nucleotide polymorphisms of infection defense gene for
           infectious complications during therapy in these patients.

        -  Reduce neurological complications by reducing doses of intrathecal methotrexate.

        -  Reduce allergic reactions against asparaginase (ASP) by using pegaspargase after E. coli
           ASP.

      OUTLINE: This is a randomized, multicenter study.

        -  Prephase: Patients are randomized to 1 of 3 treatment arms.

             -  Arm I: Patients receive doxorubicin hydrochloride IV once.

             -  Arm II: Patients receive daunorubicin hydrochloride IV once.

             -  Arm III: Patients receive daunorubicin hydrochloride IV once at a higher dose than
                in arm II.

        -  Induction phase: All patients receive vincristine IV 4 times weekly, daunorubicin
           hydrochloride IV 3 times weekly, and oral prednisolone daily for 4 weeks.

        -  Intensive phase: Patients are stratified according to risk (low vs high).

             -  Low-risk disease*: Patients receive 4 courses of methotrexate IV and asparaginase
                intramuscularly (IM).

             -  High-risk disease*: Patients receive 6 courses of cyclophosphamide IV, methotrexate
                IV, and asparaginase IM.

      All patients also receive methotrexate IV, teniposide IV, cytarabine IV, high-dose cytarabine
      IV, and asparaginase IM after completion of the above regimen.

        -  CNS phase: All patients receive intrathecal (IT) methotrexate for 3 doses and oral
           mercaptopurine for 4 weeks. Patients with T-cell acute lymphoblastic leukemia or
           patients who have blasts in cerebrospinal fluid at diagnosis or whose WBC &gt; 200/nL at
           diagnosis OR whose WBC between 100-200/nL at diagnosis and blasts &gt; 1/nL after prephase
           chemotherapy undergo cranial irradiation.

        -  Reinduction phase: Patients are stratified according to risk (low vs high)

             -  Low-risk disease*: Patients receive 2 courses of doxorubicin hydrochloride IV,
                vincristine IV, and oral dexamethasone; pegaspargase IM once; and 1 course of
                cyclophosphamide IV, cytarabine IV, and oral thioguanine.

             -  High-risk disease*: Patients receive 4 courses of doxorubicin hydrochloride IV,
                vincristine IV, and oral dexamethasone; pegaspargase IM twice; and 2 courses of
                cyclophosphamide IV, cytarabine IV, and oral thioguanine.

        -  Maintenance phase: All patients receive oral mercaptopurine daily and methotrexate IV
           once weekly for up to 2 years after diagnosis.

      NOTE: *In addition to those defined in Disease Characteristics, patients who do not achieve
      remission after induction phase are treated as high-risk disease, patients who achieve
      remission after induction phase are treated as low-risk disease

      PROJECTED ACCRUAL: A total of 550 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2003</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Dose of daunorubicin hydrochloride that is equivalent to 30 mg/m² of doxorubicin hydrochloride</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduce therapy in low-risk patients without loss of efficacy</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduce neurological complications</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduce allergic reactions against asparaginase</measure>
  </primary_outcome>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>asparaginase</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mercaptopurine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegaspargase</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teniposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thioguanine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosed with acute B-precursor or T-cell acute lymphoblastic leukemia (ALL)

          -  Meets 1 of the following risk criteria:

               -  Low-risk disease, defined by any of the following:

                    -  WBC &lt; 25/nL

                    -  B-precursor ALL

                         -  Excluding pro-B ALL

               -  High-risk disease, defined by any of the following:

                    -  WBC ≥ 25/nL

                    -  T-cell ALL or pro-B ALL

                    -  Chromosomal translocation 4/11

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  More than 7 days since prior therapy with steroids, vincristine, or daunorubicin
             hydrochloride

          -  More than 7 days since prior cytotoxic therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gritta Janka-Schaub</last_name>
    <role>Study Chair</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Evangelisches Krankenhauus Bielfeld</name>
      <address>
        <city>Biefeld</city>
        <zip>33617</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>N. Jorch, MD</last_name>
      <phone>49-52-177-278-050</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte</name>
      <address>
        <city>Bremen</city>
        <zip>D-28205</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnulf Pekrun, MD, PhD</last_name>
      <phone>49-421-497-3656</phone>
      <email>arnulf.pekrun@klinikum-bremen-mitte.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Duesseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <zip>D-40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>49-211-311-7990</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitats - Kinderklinik</name>
      <address>
        <city>Greiswald</city>
        <zip>17487</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James F. Beck, MD</last_name>
      <phone>49-383-486-6325</phone>
      <email>beck@uni-greifswald.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg - Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gritta Janka-Schaub</last_name>
      <phone>49-404-2803-2580</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kreskrankenhaus Kinderabteilung</name>
      <address>
        <city>Heide</city>
        <zip>25746</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Streitberger</last_name>
      <phone>49-481-785-911</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinic for Bone Marrow Transplantation and Hematology and Oncology</name>
      <address>
        <city>Idar-Oberstein</city>
        <zip>D-55743</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenzel Nuernberger, MD, PhD</last_name>
      <phone>49-6781-66-1582</phone>
      <email>wnuernberger@bmt-center-io.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Krefeld GmbH</name>
      <address>
        <city>Krefeld</city>
        <zip>D-47805</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P. Thomas</last_name>
      <phone>49-2151-322-375</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaets - Kinderklinik</name>
      <address>
        <city>Leipzig</city>
        <zip>D-04317</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dieter Koerholz, MD</last_name>
      <phone>49-341-9726-246</phone>
      <email>koerd@medizin.uni-leipzig.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg University</name>
      <address>
        <city>Mainz</city>
        <zip>D-55101</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P. Gutjahr, MD</last_name>
      <phone>49-6131-17-2112</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Neuwerk Klinik fuer Kinder und Jugendmedizin</name>
      <address>
        <city>Moenchengladbach</city>
        <zip>D-41066</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Mueller, MD</last_name>
      <phone>49-2161-668-2481</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. von Haunersches Kinderspital der Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>D-80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arndt Borkhardt</last_name>
      <phone>49-89-5160-4498</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Staedtisches Krankenhaus Muenchen - Harlaching</name>
      <address>
        <city>Munich</city>
        <zip>D-81545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Papucek</last_name>
      <phone>49-89-6210-2710</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik St. Hedwig-Kinderklinik</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ove Peters</last_name>
      <phone>49-941-369-5404</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Horst-Schmidt-Kliniken</name>
      <address>
        <city>Wiesbaden</city>
        <zip>D-65199</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Beron, MD</last_name>
      <phone>49-611-43-2564</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Kliniken Wuppertal University Hospital</name>
      <address>
        <city>Wuppertal</city>
        <zip>D-42283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B. Dohrn, MD</last_name>
      <phone>49-202-896-3823</phone>
      <email>bdohrn@wuppertal.helios-klinikum.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2006</study_first_submitted>
  <study_first_submitted_qc>June 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2006</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>T-cell childhood acute lymphoblastic leukemia</keyword>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Thioguanine</mesh_term>
    <mesh_term>Teniposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

